Author:
Wang Danyang,Zhang Hangyu,Xiang Tao,Wang Gang
Abstract
Colorectal cancer (CRC) is one of the most common cancers worldwide. However, the treatment outcomes of immunotherapy in microsatellite-stable (MSS) CRC remain unsatisfactory. As the majority of CRC cases display a molecular MSS/mismatch repair-proficient (pMMR) profile, it is particularly meaningful to explore the clinical applications of adaptive immune therapy in MSS CRC patients. In this review, we summarized the therapeutic approaches of adoptive immune therapies, including cytokines, therapeutic cancer vaccines, adoptive T-cell therapy, and immune checkpoint inhibitors, in the treatment of MSS CRCs.
Subject
Immunology,Immunology and Allergy
Reference72 articles.
1. Cancer Statistics, 2021;Siegel;CA Cancer J Clin,2021
2. Young-Onset Colorectal Cancer: A Review;Done;World J Gastrointest Oncol,2021
3. Cancer Treatment and Survivorship Statistics, 2019;Miller;CA Cancer J Clin,2019
4. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer;Zhang;N Engl J Med,2003
5. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome;Galon;Science,2006
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献